Search
Dexamethasone Treatment Options
A collection of 1456 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.
349 - 360 of 1456
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
ACCURATE Study for Subjects With Dry Eyes
Completed
To determine treatment and imaging outcomes in bilateral ocular surface disease management with an intracanalicular dexamethasone (0.4 mg) insert compared to standard topical over-the-counter artificial tears lubrication management
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: The Eye Center of Racine, Racine, Wisconsin
Conditions: Dry Eye Syndromes
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
Recruiting
This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Multiple Myeloma
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Active Not Recruiting
Primary Objective:
-To demonstrate the benefit of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone in the prolongation of progression free survival (PFS) as compared to bortezomib, lenalidomide, and dexamethasone, in participants with newly diagnosed multiple myeloma (NDMM) not eligible for transplant.
Secondary Objectives:
* To evaluate in both randomized (isatuximab, bortezomib, lenalidomide and dexamethasone combination (IVRd) and bortezomib, lenalidomide and dexa... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/25/2024
Locations: Investigational Site Number: 8400006, Fort Myers, Florida +103 locations
Conditions: Plasma Cell Myeloma
Treatment of Acute Lymphoblastic Leukemia in Children
Completed
RATIONALE: L-asparaginase is an important component of treatment for childhood acute lymphoblastic leukemia, but is also associated with notable side-effects, including hypersensitivity, pancreatitis, and thrombosis. We have previously reported that patients with acute lymphoblastic leukemia in whom asparaginase treatment was discontinued because of intolerable side-effects had survival outcomes that were inferior to those who received all or nearly all of their intended doses. Two bacterial sou... Read More
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
11/22/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +7 locations
Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Recruiting
This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as selinexor and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carfilzomib may stop the growth of cancer cells by blockin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Mayo Clinic (AZ), Scottsdale, Arizona +4 locations
Conditions: Refractory Multiple Myeloma
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Recruiting
Doctors leading this study hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy.
Participation in this research will last about 6 -24 months, but it may be less or more depending on your response to treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Multiple Myeloma, Relapse Multiple Myeloma
Regulation of Insulin Secretion by the GLP-1 Receptor
Terminated
AIM2: The purpose of Aim-2 of this study is to determine the role of basal GLP-1 action on the beta-cell response to insulin resistance. Healthy subjects will have fasting GLP-1 action determined with GLP-1r blockade before and after induction of experimental insulin resistance. The investigators hypothesize that fasting GLP-1 action will increase to compensate for experimental insulin resistance.
AIM3: The purpose of Aim-3 of this study is to determine the role of basal GLP-1 action on fasting... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/19/2024
Locations: Durham VA Medical Center, Durham, NC, Durham, North Carolina
Conditions: Insulin Secretion
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Recruiting
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma.
The names of the study drugs involved in this study are:
* Iberdomide (a type of cereblon E3 ligase modulator)
* Elotuzumab (a type of monoclonal antibody)
* Dexamethasone (a type of steroid)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +2 locations
Conditions: Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
Completed
The purpose of this study is to provide access to continued treatment for subjects who participated in other Astellas sponsored trials and for whom the investigator feels the subject may benefit from continued treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: Site US10004, La Jolla, California +11 locations
Conditions: Advanced Solid Tumors
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Active Not Recruiting
The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete.
This study will also investigate the effects of adding daratumumab to the combination of carfilzomib, pomalidomide and dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois +4 locations
Conditions: Multiple Myeloma
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Withdrawn
Multiple myeloma (MM) is the second most common hematologic malignancy with an estimated annual incidence of nearly 35,000 cases. While still considered an incurable disease, new treatments have improved outcomes dramatically over the last two decades. Around the turn of the millennium, classical cytotoxic chemotherapy and radiation were the only available treatment modalities and median OS was estimated at 2-3 years. Currently, there are now 17 FDA-approved anti-myeloma agents and median OS is... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Relapsed and Refractory Multiple Myeloma
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
Active Not Recruiting
This is a randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study participants) who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). Eligible participants will be randomized 1:1 into 1 of 2 study arms:
Arm SC: Isatuximab SC + Pd
Arm IV: Isatuximab IV + Pd
Participants will be allowed to co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Mohtaseb Cancer Center and Blood Disorders Site Number : 8400028, Bullhead City, Arizona +145 locations
Conditions: Plasma Cell Myeloma Recurrent
349 - 360 of 1456